Posted by Michael Wonder on 21 Jan 2025
Solid Biosciences receives FDA fast track designation for SGT-212 dual route of administration gene therapy for Friedreich’s ataxia
21 January 2025 - Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and fast track designation.
Solid Biosciences today announced that it has received fast track designation from the US FDA for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia.
